New Diabetes Drugs May Boost Ketoacidosis Risk

New Diabetes Drug May Boost Ketoacidosis Risk

The newest class of diabetes drugs on the market may increase a patient’s risk for developing a serious complication of the disease that can potentially be fatal.

Researchers found that type 2 diabetes patients taking SGLT2 inhibitors – which include Farxiga (dapagliflozin), Invokana (canagliflozin) and Jardiance (empagliflozin) – were twice as likely to experience diabetic ketoacidosis compared to people who were taking another type of diabetes medication. In diabetic ketoacidosis, a patient has high levels of acids known as ketones in the blood. Symptoms include vomiting, abdominal pain, shortness of breath and brain swelling.

Researchers came to their conclusion after looking at 40,000 people taking an SGLT2 inhibitor, and then comparing results to those on a DPP-4 inhibitor. Drugs in the latter group include Januvia (sitagliptin), Onglyza (saxagliptin) and Tradjenta (linagliptin).

After 180 days, 26 patients taking a DPP-4 inhibitor were diagnosed with diabetic ketoacidosis compared to 55 individuals taking SGLT2 inhibitors, they reported in the New England Journal of Medicine. Study authors, however, noted that the rate of ketoacidosis is still very small with SGLT2 inhibitors.

“This is a side effect that’s usually seen in patients with type 1 diabetes mellitus – not type 2 – so doctors are not ‘on the lookout’ for it,” lead author Michael Fralick, MD, of Boston’s Brigham and Women’s Hospital, said in a statement. “That means that the risk of this side effect might actually be even higher than what we found due to misdiagnosis/under recording.”


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

Flouride, PPIs, Breast Density and Prostate Cancer

Flouride, PPIs, Breast Density and Prostate Cancer

Startling news about fluoride, a study encourages more limites use of PPIs, does knowing the density of your breasts matter, and vegetables aren’t helpful in warding off prostate cancer (darn).  Be Well.  Fluoride and Pregnancy The medical community was shocked at the conclusions of two new studies on fluoride’s effect…

  • Advertisement